Analyst Research

Report Title Price
Provider : Thomson Reuters Stock Report
Provider : GlobalData
Provider : ValuEngine, Inc.
Provider : Pechala's Reports

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

OncoMed receives orphan drug designation from the FDA for Demcizumab in pancreatic cancer

Friday, 2 May 2014 08:30am EDT 

OncoMed Pharmaceuticals Inc:Says U.S. Food and Drug Administration (FDA) Department of Orphan Products Development has granted orphan drug designation to demcizumab (anti-DLL4, OMP-21M18) for the treatment of pancreatic cancer.Currently conducting a Phase 1b clinical trial of demcizumab in combination with Abraxane(nab-paclitaxel) and gemcitabine in first-line Stage IV pancreatic cancer patients. 

Company Quote

0.69 +3.01%
1:00pm EST